共 8 条
[1]
Mahon JL,Laupacis A,Hodder RV,et al.Theophyline for irreversible chronic airflow limitation: a randomized study comparingn of 1 trials to standard practice. Chest . 1999
[2]
Mahler DA,Donohue JF,Barbee RA,et al.Efficacy of salmeterol xinafoate in the treatment of COPD. Chest . 1999
[3]
Burge PS.EUROSCOP, ISOLDE and the Copenhagen city lung study[editorial]. Thorax . 1999
[4]
Friedman M,Serby C,Menjoge S,et al.Pharmoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest . 1999
[5]
Friedman M and Hilleman DE.Economic burden of chronic obstructive pulmonary disease: Impact of new treatment options. Pharmacoeconomics . 2000
[6]
Campbell S.For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Archives of Internal Medicine . 1999
[7]
Vestbo J,Sorensen T,Lange P,et al.Long- term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. The Lancet . 1999
[8]
Pauwels RA,Lofdahl CG,Laitinen LA,et al.Long - term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking.European Respiratory Society study on chronic obstructive pulmonary disease. The New England Journal of Medicine . 1999